Saltar a casilla de búsquedaSaltar a navegaciónIr directamente al contenido principal

Spinal cord injury sequelae alter drug pharmacokinetics: An overview

  • H. Mestrec(Autor)
    ,
  • T. Alkonc(Autor)
    ,
  • S. Salazarc(Autor)
    ,
  • A. Ibarrab, a(Autor)
Research Output: Contribución a una revista Artículo de revisión Revisión por expertos

Acceso abierto

Publication Information

Tipo de resultado

Research Output: Contribución a una revista Artículo de revisión Revisión por expertos

Idioma original

Inglés

Páginas desde-hasta (Número de páginas)

Páginas 955-960 (6 páginas)

Revista (Volumen, Número de Edición)

Spinal Cord (Volumen 49, Número 9)

Hitos de publicación

  • Publicada - 01/09/2011

Estado de publicación

Publicada - 01/09/2011

ISSN

1362-4393

ID de publicación externa

  • Scopus: 80052393320
  • PubMed: 21625241

Abstract

Study design:Literature review.Objectives:Critical review of the literature published on the physiological alterations caused by spinal cord injury (SCI) and their effect on the pharmacokinetic parameters of commonly employed drugs. The review introduces the most recent treatment protocols of a variety of drugs, enabling the modern clinician to apply efficacious and cost-effective solutions to the pharmacological treatment of SCI patients.Methods:Studies published in international indexed journals up to January 2011 were selected from the PubMed database.Results:The review evaluated the sequelae of SCI and their effect on pharmacological processes. The results demonstrated that these alterations affected the pharmacokinetics of drugs commonly administered to SCI patients, such as antibiotics, muscle relaxants, immunosuppressants and analgesics.Conclusion:There are multiple etiologies to SCI and patients present with varying degrees of impairment. Factors such as level of injury and completeness of the injury create a very heterogeneous population within the SCI community. The heterogeneity of this population creates a problem when trying to standardize pharmacokinetic (PK) parameters. It is because of this that specific physiological alterations must be linked to changes in PK and be identified within the clinical setting. This relationship between physiology and PK enables the clinician to be alert for possible pharmacological complications in individual patients based on their clinical manifestations. Future research should aim to develop rigorous therapeutic guidelines tailored to the diverse manifestations of SCI so as to provide effective, affordable and safe pharmacotherapy.